Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination.
about
Discriminative stimulus properties of indorenate, a serotonin agonist.Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide YThe drug treatment of delayed ejaculationCardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic miceEffects of yohimbine on the antinociceptive and place conditioning effects of opioid agonists in rodentsNoradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats.Yohimbine anxiogenesis in the elevated plus maze is disrupted by bilaterally disconnecting the bed nucleus of the stria terminalis from the central nucleus of the amygdalaNeurobiological findings in posttraumatic stress disorder: a review.The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats.Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs.Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbineYohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortexInvolvement of selective alpha-2 adrenoreceptor in sympathetically maintained painThe 5-HT1A receptor and the stimulus effects of LSD in the rat.Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular diseaseModulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors.Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197).Characterization of the hypothermic effects of imidazoline I₂ receptor agonists in ratsYohimbine is a 5-HT1A agonist in rats in doses exceeding 1 mg/kg.Effects of noradrenergic alpha-2 receptor antagonism or noradrenergic lesions in the ventral bed nucleus of the stria terminalis and medial preoptic area on maternal care in female ratsThe use of the reinstatement model to study relapse to palatable food seeking during dieting.The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves.A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
P2860
Q24535719-CEF41589-5A43-431F-9CC3-C1EF765D04E5Q24620764-A4A0470B-5D15-4DBA-81D9-BFBFD7DE8D8FQ24635197-BDC435C4-C194-4BCD-9789-56028CB9789EQ28075054-B49B981C-9609-45A8-8D36-FF9584C51506Q28343284-EAB16FA6-4373-42F8-85D2-529C02D56143Q28363862-FFDED124-F164-4B7C-8378-52695A864359Q30433556-FBDCDDFE-105C-42B7-BA95-5D93AB9741D3Q30448030-D0C66E61-67FC-4236-A8C4-CB79CF8F264FQ30473432-DE265DDF-BD27-4336-8ABA-0950EBA6974CQ30479808-B7600FE3-1865-466D-BB2C-9CDDBE714284Q30481352-A86791AB-95A1-4EEA-B045-F3A888DEAA51Q30491998-645CF3BE-E13D-41A0-B141-70A2C5BE6B37Q33847097-40DEB8A1-ABCE-497C-BE7D-30CE91739FBBQ33906803-0D2AF86C-2BBE-45ED-9CFB-A586F3FC9B8AQ33938466-D38CF8CD-E696-4219-8104-293D19368433Q33970101-3C90FC08-2643-4058-8199-1065A4EB96C9Q34099158-62045758-7377-4D19-83BC-90223D6416E0Q34130038-3E0A8507-FDF5-4727-AFC5-CCCAB0188E28Q34314025-9D96BDF5-C494-441B-9E9E-9C27CB036A57Q35041626-F35B54BF-B22B-4FB7-BC4A-BE64537CBE9CQ35873531-2D05A686-C7FE-408F-A83E-E617C3179A3BQ36110606-46A116EF-3AFF-4364-9793-0664CC988272Q36501331-832C4F78-990D-4C98-B007-396AD9ADA820Q36838912-C3B85392-0A48-4575-956D-0D110B667DB9Q37203397-639B3EBD-EC01-4BA2-9233-E8DCCB90D0ECQ40446321-68804B11-FE60-42A6-9577-D4310D57F5FBQ42134540-87BFB725-2668-4F9D-8555-A80DF0D54739Q42708483-EBF57BC1-8FC4-42C4-B4AD-0A0D56B08CF2Q58788199-AAA0DDF0-A0EC-408F-808A-C7FB6B6951B4
P2860
Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@en
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@nl
type
label
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@en
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@nl
prefLabel
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@en
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@nl
P1476
Yohimbine as a serotonergic ag ...... nding and drug discrimination.
@en
P2093
P304
P407
P577
1992-11-01T00:00:00Z